[go: up one dir, main page]

WO2007042669A3 - DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl - Google Patents

DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl Download PDF

Info

Publication number
WO2007042669A3
WO2007042669A3 PCT/FR2006/002286 FR2006002286W WO2007042669A3 WO 2007042669 A3 WO2007042669 A3 WO 2007042669A3 FR 2006002286 W FR2006002286 W FR 2006002286W WO 2007042669 A3 WO2007042669 A3 WO 2007042669A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkylene
alkyl
aryl
optionally substituted
nrarb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2006/002286
Other languages
English (en)
Other versions
WO2007042669A2 (fr
Inventor
Jean-Michel Augereau
Gilles Courtemanche
Pierre Despeyroux
Michel Geslin
Anne Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Sanofi Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007042669(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur SA filed Critical Sanofi Pasteur SA
Publication of WO2007042669A2 publication Critical patent/WO2007042669A2/fr
Publication of WO2007042669A3 publication Critical patent/WO2007042669A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des dérivés de la 4-amino-quinazoline, de formule générale (I). dans laquelle : A , B = C1-4-alkylène éventuellement substitué ; L = liaison simple, C1-2- alkylène, -CH=CH- ou -C=C- ; les groupes C1-2 alkylene et -CH=CH- étant éventuellement substitués, ou L = cycloprop-1 ,2-diyle ; R = H, C1-5-alkyle, C1-3- fluoroalkyle, C3-6-cycloalkyle, -C(O)C1-3-alkyle, C1-3-alkylène-C3-6--cycIoalkyle, -CH2-C=CH, C2-4-alkylène-NRaRb. C1-3-alkylène-X-C1-3-alkyle où X = O, SO2 ; R1 = aryle ou hétéroaryle ; éventuellement substitués ; R2 et R3 = H, C1-3-alkyle ou C1-3-fluoroalkyle, ou bien R2 et R3 forment ensemble un cycloprop-1 ,1-diyle ; R4 = H, C1-5-alkyle, C1-3- fluoroalkyle, C1-5-alcoxy, -SF5, C1-3-alkylène-X-C1-3-alkyle où X = O ou SO2, C1-5-alkylène- NRaRb. un aryle ou un hétéroaryle éventuellement substitués ; R5 = H, halogène, C1-5- alkyle, 1-3-fluoroalkyle, C1-5-alcoxy, C3-6 cycloalkyle, C1-3 alkylène-C3-6 cycloalkyle, C1-3- alkylène-O-C1-3-alkyle, C1-3-alkylène-(OH), C1.3-alkylène-X-C1-3-alkyle où X = S, SO ou SO2, ou bien R5 = -NRaRb, C1-3 a-alkylèπe-NRaRb, aryle, C1-3-alkylène-aryle, -O-aryle, C1-3- alkylène-O-aryle, C1-3-alkylène-O-C1-3-alkylène-aryle, hétéroaryle ou C1-3-alkylène- hétéroaryle éventuellement substitués, ou R5 = hétérocycle éventuellement substitué par C1-3-alkyle, -C(O)C1-3-alkyle, -C(O)C1-3 fluoroalkyle , C1-3-alkylène-C3-6-cycloalkyle, C1-3- alkylène-aryle, C1-3-alkylène-hétéroaryle éventuellement substitués ; R7 = H, halogène, C1-5 alkyle, C1-3 fluoroalkyle, C1-5 alcoxy, -COOH, (O)O-C1-3-s-alkyle, C1-3 fluoroalcoxy, C1-3-alkylène-(OH), -NO2, -CN, -X-C1-3-alkyle où X représente S, SO ou SO2, ou bien R7 = -NRaRb, C1-3-alkylène-NRaRb, -C(O)-NRaRb -C(O)-C1-3-alkyle, aryle, -O-aryle ou hétéroaryle éventuellement substitués ; à l'état de base ou de sel d'addition à un acide, ainsi qu'à l'état d'hydrate ou de solvat, ainsi que leur procédé de préparation et leur utilisation comme modulateurs des récepteurs MCH 1 pour le traitement de l'obésité, de f anxiété, de la dépression, etc.
PCT/FR2006/002286 2005-10-12 2006-10-11 DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl Ceased WO2007042669A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0510409A FR2891829A1 (fr) 2005-10-12 2005-10-12 Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
FR0510409 2005-10-12

Publications (2)

Publication Number Publication Date
WO2007042669A2 WO2007042669A2 (fr) 2007-04-19
WO2007042669A3 true WO2007042669A3 (fr) 2007-05-31

Family

ID=36645639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/002286 Ceased WO2007042669A2 (fr) 2005-10-12 2006-10-11 DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl

Country Status (5)

Country Link
AR (1) AR056688A1 (fr)
FR (1) FR2891829A1 (fr)
TW (1) TW200732308A (fr)
UY (1) UY29857A1 (fr)
WO (1) WO2007042669A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666193A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation
EP2300456A1 (fr) * 2008-05-22 2011-03-30 Allergan, Inc. Composés bicycliques ayant une activité sur le récepteur cxcr4
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3429585B1 (fr) 2016-03-16 2021-11-24 Kura Oncology, Inc. Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
FI3429591T3 (fi) 2016-03-16 2023-06-15 Kura Oncology Inc Substituoituja tieno[2,3-d]pyrimidiinijohdannaisia meniini-mll:n estäjinä ja käyttömenetelmiä
WO2018175746A1 (fr) 2017-03-24 2018-09-27 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (fr) 2017-09-20 2019-03-28 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001151A1 (fr) * 1982-09-24 1984-03-29 Beecham Group Plc Derives d'amino-azabicycloalkyle utilises en tant qu'antagonistes de la dopamine
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2003028641A2 (fr) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Antagonistes du recepteur de la mch
WO2003106452A2 (fr) * 2002-06-12 2003-12-24 Millennium Pharmaceuticals, Inc. Antagonistes du recepteur de l'hormone de melano-concentration
WO2004052371A2 (fr) * 2002-12-11 2004-06-24 7Tm Pharma A/S Composes de quinoline cycliques utilises avec des troubles lies au recepteur mch
WO2004078733A1 (fr) * 2003-03-03 2004-09-16 Vertex Pharmaceuticals Incorporated Quinazolines utilisees comme modulateurs de canaux ioniques
WO2006071095A1 (fr) * 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984001151A1 (fr) * 1982-09-24 1984-03-29 Beecham Group Plc Derives d'amino-azabicycloalkyle utilises en tant qu'antagonistes de la dopamine
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO2003028641A2 (fr) * 2001-10-01 2003-04-10 Taisho Pharmaceutical Co., Ltd. Antagonistes du recepteur de la mch
WO2003106452A2 (fr) * 2002-06-12 2003-12-24 Millennium Pharmaceuticals, Inc. Antagonistes du recepteur de l'hormone de melano-concentration
WO2004052371A2 (fr) * 2002-12-11 2004-06-24 7Tm Pharma A/S Composes de quinoline cycliques utilises avec des troubles lies au recepteur mch
WO2004078733A1 (fr) * 2003-03-03 2004-09-16 Vertex Pharmaceuticals Incorporated Quinazolines utilisees comme modulateurs de canaux ioniques
WO2006071095A1 (fr) * 2004-12-31 2006-07-06 Sk Chemicals Co., Ltd. Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité

Also Published As

Publication number Publication date
WO2007042669A2 (fr) 2007-04-19
FR2891829A1 (fr) 2007-04-13
UY29857A1 (es) 2007-05-31
TW200732308A (en) 2007-09-01
AR056688A1 (es) 2007-10-17

Similar Documents

Publication Publication Date Title
WO2007042669A3 (fr) DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl
WO2008071918A8 (fr) Dérivés de pyrido-pyrazine utiles en tant que composés herbicides
WO2006007532A3 (fr) Composes heteroaryles substitues en 2
NO20074093L (no) Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav
MX2010005109A (es) Compuestos herbicidas.
EA200501477A1 (ru) Производные пиперидинил- и пиперазинилалкилкарбаматов, способы их получения и применение их в терапии
JP2009530268A5 (fr)
WO2006108695A3 (fr) Composes de sulfoximines macrocycliques et leurs sels, compositions pharmaceutiques comprenant lesdits composes, leurs procedes de preparation et leurs utilisations
WO2009154754A3 (fr) Synthèse de dérivés de morpholine deutérés
CO6460742A2 (es) Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica
WO2007042660A3 (fr) Dérivés de la 1-amino-phtalazine substituee, leur préparation et leur application en thérapeutique
WO2008009750A3 (fr) Composés macrocycliques utiles comme inhibiteurs de la bace
TW200617000A (en) Methods of making 2,6-diaryl piperidine derivatives
TW200637860A (en) Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
WO2008003855A3 (fr) Utilisation de 2-benzoyl-imidazopyridines en thérapeutique
JP2012503653A5 (fr)
WO2009106750A3 (fr) Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren
WO2006066956A3 (fr) Macrocycles sulfonamido utilises comme inhibiteurs de tie2 et sels de ceux-ci, composition pharmaceutique renfermant ces composes, procede de preparation et utilisation de celle-ci
WO2006066044A3 (fr) Procedes de production de 4-aminoquinazolines
IL188796A0 (en) Derivatives of 5-pyridinyl-1-azabicyclo[3,2,1] octane, preparation method thereof and use of same in therapeutics
WO2010067010A3 (fr) Derives de morphine-6-glucuronide, leur preparation et leur application en therapeutique
ATE515502T1 (de) Verfahren zur herstellung von tetranorlabdanderivaten
DE602004008486D1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-ä2-amino-6-chlor-9h-purin-9-ylü-2-cyclopenten-1-methanol
WO2009106751A3 (fr) Dérivés de n-heterocyclique-6-heterocyclique-imidazo[1,2- a]pyridiνe-2-carb0xamides, leur préparation et leur application en thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06820187

Country of ref document: EP

Kind code of ref document: A2